Integra Lifesciences Holdings vs Penumbra
Integra Lifesciences Holdings is the larger business, with $1.64bn of revenue in fiscal 2025 against $1.40bn for Penumbra (1.2 times as much). Penumbra grew faster (17.5% against 1.5%). Penumbra kept more of each dollar of sales as profit: a net margin of 12.7% against -31.6%. Penumbra carries less debt relative to equity (0.0% against 165.8%).
| Latest fiscal year | Integra Lifesciences HoldingsIART, 2025 | PenumbraPEN, 2025 |
|---|---|---|
| Revenue | $1.64bn | $1.40bn |
| Revenue growth | 1.5% | 17.5% |
| Net income | −$516m | $178m |
| Operating margin | -30.2% | 13.5% |
| Net margin | -31.6% | 12.7% |
| Return on equity | -39.9% | 13.8% |
| Free cash flow | −$31.1m | $175m |
| Cash | $235m | $187m |
| Total debt | $1.73bn | $0 |
| Debt to equity | 165.8% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $221,000 | $0 |
| Employees | — | 4,700 |
| Market value | $1.07bn | $12.69bn |
| Price vs our value range | — | Above our value range |
| Moat score | 51 (Moderate) | 44 (Weak) |
| Insider trades, 12 months | 1 buys, 0 sales | 0 buys, 32 sales |